Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease by De Gasperi, Rita et al.
RESEARCH ARTICLE Open Access
Presenilin-1 regulates induction of hypoxia
inducible factor-1a: altered activation by a
mutation associated with familial Alzheimer’s
disease
Rita De Gasperi
1,3, Miguel A Gama Sosa
1,3, Stella Dracheva
1,3, Gregory A Elder
2,3,4*
Abstract
Background: Mutations in presenilin-1 (Psen1) cause familial Alzheimer’s disease (FAD). Both hypoxia and ischemia
have been implicated in the pathological cascade that leads to amyloid deposition in AD. Here we investigated
whether Psen1 might regulate hypoxic responses by modulating induction of the transcription factor hypoxia
inducible factor 1-a (HIF-1a).
Results: In fibroblasts that lack Psen1 induction of HIF-1a was impaired in response to the hypoxia mimetic cobalt
chloride, as well as was induction by insulin and calcium chelation. Reintroduction of human Psen1 using a
lentiviral vector partially rescued the responsiveness of Psen1-/- fibroblasts to cobalt chloride induction. HIF-1a
induction did not require Psen1’s associated g-secretase activity. In addition, the failure of insulin to induce HIF-1a
was not explicable on the basis of failed activation of the phosphatidylinositol 3-kinase (PI3K/Akt) pathway which
activated normally in Psen1-/- fibroblasts. Rather we found that basal levels of HIF-1a were lower in Psen1-/-
fibroblasts and that the basis for lower constitutive levels of HIF-1a was best explained by accelerated HIF-1a
degradation. We further found that Psen1 and HIF-1a physically interact suggesting that Psen1 may protect HIF-1a
from degradation through the proteasome. In fibroblasts harboring the M146V Psen1 FAD mutation on a mouse
Psen1 null background, metabolic induction of HIF-1a by insulin was impaired but not hypoxic induction by cobalt
chloride. Unlike Psen1-/- fibroblasts, basal levels of HIF-1a were normal in FAD mutant fibroblasts but activation of
the insulin-receptor pathway was impaired. Interestingly, in Psen1-/- primary neuronal cultures HIF-1a was induced
normally in response to cobalt chloride but insulin induction of HIF-1a was impaired even though activation of the
PI3K/Akt pathway by insulin proceeded normally in Psen1-/- neuronal cultures. Basal levels of HIF-1a were not
significantly different in Psen1-/- neurons and HIF-1a levels were normal in Psen1-/- embryos.
Conclusions: Collectively these studies show that Psen1 regulates induction of HIF-1a although they indicate
that cell type specific differences exist in the effect of Psen1 on induction. They also show that the M146V
Psen1 FAD mutation impairs metabolic induction of HIF-1a, an observation that may have pathophysiological
significance for AD.
Background
Alzheimer’s disease (AD) is a neurodegenerative disor-
der characterized clinically by progressive loss of mem-
ory along with other cognitive skills and pathologically
by accumulation of amyloid plaques and neurofibrillary
tangles [1]. While most cases occur sporadically some
are inherited in an autosomal dominant fashion. Familial
cases (FAD) exhibit similar clinical and pathological fea-
tures as the sporadic disease but have a generally earlier
age of onset [2].
The presenilin-1 gene (Psen1) was discovered because
mutations in it and a homologous gene presenilin-2
(Psen2) cause FAD [2]. To date more than 170 different
mutations in Psen1 have been associated with FAD [3].
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cause of early onset FAD accounting for probably 50%
of all autosomal dominant cases [4]. Mutations in Psen2
are a less common cause of FAD [2].
The pathophysiological cascade in AD includes
deposition of β-amyloid (Aβ)i nc o m p a c ta n dd i f f u s e
plaques as well as production of oligomeric forms of
Aβ that are currently thought to be the most toxic
species [5]. The factors that trigger the amyloid cas-
cade remain incompletely understood. Recently there
has been interest in the role that vascular disease
might play in this process [6]. Indeed an array of epi-
demiologic evidence supports an association between
vascular disease and its risk factors with cognitive
impairment and AD [6] and postmortem studies have
shown that AD is complicated by vascular pathology in
about one-third of cases [7].
These observations could be explained by viewing vas-
cular disease as a co-morbidity that acts in an additive
fashion with AD pathology to exacerbate ongoing cogni-
tive decline. Alternatively vascular disease might lead to
hypoxia/ischemia that might drive AD pathology itself.
Supporting the latter hypothesis both hypoxia and ische-
mia increase amyloid precursor protein (APP) expres-
sion as well as shunt APP processing towards Aβ
production [8-13]. Hypoxia also decreases expression of
the a-secretase, ADAM-10 [11] while increasing expres-
sion of the principal β-secretase, BACE1 [14,15].
Thus aberrant or inefficient hypoxic responses in
brain might contribute to AD initiation or progression.
The brain’s response to hypoxia involves a multiplicity
of pathways that as in other tissues includes induction
of a set of genes regulated by the transcription factor
hypoxia inducible factor-1 (HIF-1) [16,17]. HIF-1 is a
dimer that consists of a and β subunits. Levels of HIF-
1a are regulated by oxygen availability while HIF-1β
subunits are constitutively expressed with the level of
HIF-1 transcriptional activity regulated primarily by
levels of HIF-1a. HIF-1 is a key transcriptional regulator
of a broad range of cellular genes that mediate
responses to hypoxia. Although originally discovered as
an hypoxia induced factor, HIF-1a also increases in
response to stimulation by a number of metabolic/
growth factor signaling pathways including insulin and
insulin like growth factor-1 (IGF-1) [18-23]. Interestingly
both Psen1 and Psen2 are induced by hypoxia [24-26]
and Psen1 has been suggested to regulate signaling
through a number of growth factor related pathways
[27-29]. In addition HIF-1a mRNA was found reduced
in a hypomorphic Psen1 mouse mutant [30,31]. Here we
investigated whether Psen1 might regulate hypoxic
responses and show that Psen1 influences both hypoxic
and metabolic/growth factor induction of HIF-1a in
cells that lack Psen1 although the effects vary in a cell
type dependent manner. We also show that a Psen1
FAD mutation alters metabolic induction of HIF-1a.
Results
Impaired induction of HIF-1a in fibroblasts lacking Psen1
Psen1 and Psen2 are induced by hypoxia [24-26] sug-
gesting that presenilins may play a role in cellular adap-
tation to hypoxia. HIF-1a is induced by hypoxia and is
a key transcriptional regulator of a broad range of cellu-
lar genes that mediate cellular responses to hypoxia
[16,17]. To determine whether Psen1 might affect HIF-
1a induction we treated Psen1+/+ and Psen1-/- immor-
talized mouse embryonic fibroblasts with CoCl2.C o b a l t
chloride mimics the hypoxic activation of HIF-1a by
interfering with binding of the iron group that along
with oxygen is required for activity of the prolyl hydro-
xylases (PHDs), that target HIF-1a for proteasomal
degradation [32]. When the time course of induction
was analyzed it was found that HIF-1a induction
was maximal between 2-4 hours after treatment of
Psen1 +/+ cells, while Psen1-/- cells showed consider-
ably less HIF-1a at all time points (Figure 1A). At 4
hours after treatment HIF-1a levels were approximately
seven-fold higher in Psen1+/+ fibroblasts compared to
Psen1-/- fibroblasts (p = 0.02; Figure 1B, C).
Besides its effects on hypoxia-induced responses HIF-
1a also mediates metabolic and growth factor signaling
[33]. For example both IGF-1 and insulin stimulate HIF-
1a accumulation [21,34]. To test whether Psen1 might
also influence non-hypoxic signaling we stimulated
Psen1+/+ and Psen1-/- fibroblasts with insulin. HIF-1a
increased over four-fold in Psen1+/+ fibroblasts (p =
0 . 0 2 ;F i g u r e1 D ,E ) .B yc o n t r a s tH I F - 1 a elevated only
slightly in Psen1-/- fibroblasts (p = 0.04) and induced
levels were more than eight-fold lower in Psen1-/- cells
than in Psen1+/+ cells (p = 0.0002).
HIF-1a is also induced when cellular calcium levels
are lowered [35]. To test whether lack of Psen1 might
affect induction of HIF-1a in response to altered cal-
cium levels we treated Psen1+/+ and Psen1-/- fibroblasts
with the calcium chelator BAPTA. As shown in figure
1F, Psen1-/- fibroblasts activated HIF-1a less than Psen1
+/+ fibroblasts following calcium chelation.
HIF-1a has many downstream targets [17]. To deter-
mine whether the reduced induction of HIF-1a in
Psen1-/- fibroblasts affected activation of HIF-1a target
genes, we examined activation of the HIF-1a targets,
vascular endothelial growth factor (Vegf) and the glu-
cose transporter-1 (Glut-1) [17] by qPCR. At baseline
neither Vegf nor Glut-1 RNA differed between Psen1
+/+ and Psen1-/- cells (p = 0.43 Vegf; p = 0.38 Glut-1,
unpaired t-tests). As shown in Figure 2A, following
treatment of Psen1+/+ cells with cobalt chloride, Vegf
RNA was elevated over four-fold at 3 hours post-
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Page 2 of 20Figure 1 Impaired induction of HIF-1a in Psen1-/- immortalized mouse embryonic fibroblasts.I np a n e lA ,t h et i m ec o u r s eo fH I F - 1 a
induction in Psen1+/+ (wt) and Psen1-/- (-/-) immortalized mouse embryonic fibroblasts is shown. Cultures were treated with 100 μm cobalt
chloride for the indicated times (min). Lysates were prepared and Western blotting was performed using an anti-HIF-1a antibody. The lower
panel shows the blot reprobed for β-tubulin. A representative blot is shown from experiments that were performed multiple times. In panels B
and C, Psen1+/+ (wt) and Psen1-/- (-/-) cultures were treated with 100 μm cobalt chloride for 4 hours and analyzed for HIF-1a as in (A). The
lowest panel in B shows representative samples of wt and -/- fibroblasts probed with the Psen1 antibody 33B10 to confirm the lack of detectible
Psen1 expression in Psen1-/- fibroblasts. Panel C shows quantitation of the levels of HIF-1a in data derived from four independent experiments.
In panels D and E cultures were serum starved overnight and then treated with insulin for 4 hours after which lysates were prepared and
Western blotting performed as in (A). Panel E shows quantitation of the experiment shown in (D). In panel F, Psen1+/+ and Psen1-/- fibroblasts
were treated with BAPTA-AM for 1.5 hours. Results from an experiment performed in triplicate is shown. The lower panel shows the blot
reprobed for β-tubulin. All panels show representative blots from experiments that were performed multiple times. Western blots for HIF-1a
were performed using a rabbit polyclonal antibody. The quantitative results are expressed as the ratio of HIF-1a to β-tubulin and are presented
as + SEM. Asterisks in panels C and E indicate values that are different from the corresponding untreated cells (p < 0.05, unpaired t-tests). Other
statistical comparisons are discussed in the text.
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elevated compared to baseline (F3, 14 =7 4 . 4 6 ,p<
0.0001; p < 0.01 all treated groups vs. baseline, Dun-
nett’s test). By contrast, while Vegf RNA was elevated
in Psen1-/- fibroblasts after treatment with cobalt
chloride (F3, 14 = 27.59, p < 0.0001), the response was
blunted rising to only≈ 1.8 fold at 3 hours (p < 0.05,
Dunnett’st e s t ) ,≈ 2 . 4f o l da ts i xh o u r s( p<0 . 0 1 )a n d≈
3.3 fold at 16 hours (p < 0.01). At 3 hours post-treat-
ment Vegf RNA was approximately 2.5-fold higher in
Psen1+/+ compared to Psen1-/- cells (p = 0.01,
unpaired t-test with Welch correction). Interestingly at
16 hours post-treatment levels in Psen1-/- were not
significantly different from those in Psen1+/+ cells
(p = 0.054, unpaired t-test).
Very similar results were seen with Glut-1 (Figure 2B).
In wild type cells Glut-1 RNA became maximally ele-
vated at 3 hours and continued to be increased over
baseline at six and 16 hours (F3, 14 = 45.14, p < 0.0001,
p < 0.01 all treated groups vs. control, Dunnett’s test).
By contrast while increasing in Psen1-/- fibroblasts (F3,
14 = 15.12, p = 0.0001), a blunted response was seen
with no change in Glut-1 RNA at 3 hours post-treat-
ment and a maximal induction that was delayed and
was only approximately 60% of that seen in Psen1+/+
cells at 3 hours. Thus while Psen1-/- fibroblasts are not
unresponsive to cobalt chloride they clearly show a
blunted response with only prolonged exposures produ-
cing the levels of induction seen in wild type cells at
shorter times, which is consistent with the lower levels
of HIF-1a induced by this treatment.
To determine whether reintroduction of Psen1 could
improve HIF-1a responsiveness in Psen1-/- fibroblasts,
cells were infected with Psen1-expressing lentiviruses for
48 hours and subsequently treated for 4 hours with
cobalt chloride. As shown in Figure 3, reintroduction of
Psen1 resulted in an approximately 2.8 fold increase in
basal HIF-1a levels in Psen1-/- cells (p = 0.04, unpaired
t-test) and following treatment with cobalt chloride
there was an increase in HIF-1a in both non-infected as
well as infected cells (p < 0.0001 non-infected; p = 0.001
infected). However there was a more than two-fold
increase in HIF-1a levels in infected as compared to
non-infected cells that were grown and treated in paral-
lel (p = 0.02).
We have also seen less HIF-1a induction in fibroblast
cell lines lacking both presenilins (Psen-/-)i nr e s p o n s e
to cobalt chloride and insulin (Figure 4). Therefore
these results as well as the increased responsiveness of
Psen1-/- fibroblasts following reintroduction of Psen1
argue against the possibility that the observations are
Figure 2 Reduced activation of HIF-1a downstream target
genes in Psen1-/- fibroblasts treated with cobalt chloride.
Psen1+/+ (wt) or Psen1-/- fibroblasts were treated with cobalt
chloride for the indicated times (hours). Levels of Vegf (A) and
Glut-1 (B) RNA were determined by qPCR (n = 9 cultures per
group untreated; n = 3 per group treated). (*) indicates p < 0.05
and (**) p < 0.01 vs. untreated control by Dunnett’s post-test.
Statistical comparisons between groups are discussed further in
the text.
De Gasperi et al. Molecular Neurodegeneration 2010, 5:38
http://www.molecularneurodegeneration.com/content/5/1/38
Page 4 of 20the result of a purely clonal effect. Rather these results
argue that fibroblasts lacking Psen1 are hyporesponsive
to a range of HIF-1a inducers and that this hypoactiva-
tion has functional consequences for the induction of
HIF-1a target genes.
HIF-1a induction does not require g-secretase activity
Psen1 is best known for its role in g-secretase activity [36].
Interestingly both the insulin [37] and IGF-1 [38] recep-
tors are substrates for g-secretase cleavage. In both cases
these cleavages have been suggested to generate intracellu-
lar domains (ICDs) that may be involved in cellular signal-
ing. To determine whether insulin induced activation of
HIF-1a might require Psen1’s associated g-secretase activ-
ity, Psen1+/+ fibroblasts were treated with the g-secretase
inhibitor XXI for 16 hours in serum free media and then
stimulated with insulin for four hours. As shown in Figure
5 (5A and 5C) HIF-1a decreased modestly following treat-
ment with inhibitor XXI alone (p = 0.006, unpaired t-test)
but was activated to the same extent whether inhibitor
was present or not (p = 0.29). To ensure the adequacy of
g-secretase treatment blots were stripped and reprobed
with an antibody that detects the C-terminal fragment
(CTF) of N-cadherin. This fragment is generated by the
sequential cleavage of N-cadherin by a metalloproteinase
followed by g-secretase and its appearance is stimulated
when g-secretase activity is blocked [39]. As expected,
N-cadherin CTFs accumulated in Psen1+/+ samples trea-
ted with inhibitor XXI but not in untreated controls
(Figure 5A, bottom panel). Cobalt chloride induced activa-
tion of HIF-1a was also not affected by treatment of Psen1
+/+ fibroblasts with the g-secretase inhibitor L-685,459
(Figure 5B). Thus impaired g-secretase activity does not
appear to explain the reduced HIF-1a induction in
Psen1-/- cells.
Normal activation of PI3K/Akt by IGF-1 and insulin in
Psen1-/- fibroblasts
Growth factor stimulation principally increases HIF-1a
protein synthesis by stimulating transcription/transla-
tion while degradation proceeds at a constant rate.
Figure 3 Reintroduction of Psen1 into Psen1-/- fibroblasts.
Psen1-/- fibroblasts were infected with lentiviruses carrying the
human Psen1 cDNA (hPS1-LV) for 24 hours and grown in complete
medium for 48 hours. The infected cells were then treated for 4
hours with 100 μM cobalt chloride along with non-infected Psen1-/-
cells grown in parallel. The cells were lysed and analyzed for HIF-1a
induction by Western blot using anti HIF-1a polyclonal antibodies.
Blots were reprobed for anti β-tubulin as a loading control. Psen1
expression was analyzed using the NT.1 mouse monoclonal
antibody. FL: full length, NTF: N-terminal fragment. A representative
blot is shown in panel A. Panel B shows quantitation of the HIF-1a
response (n = 3 samples per group non-infected; n = 4 infected). P
values (unpaired t-tests) are indicated for selected comparisons
which are discussed further in the text.
Figure 4 Impaired induction of HIF-1a in immortalized mouse
embryonic fibroblasts lacking both Psen1 and Psen2. Wild type,
Psen1-/- (PS1-/-) and Psen1/Psen2-/- (PS-/-) immortalized fibroblasts
were treated with 100 μm cobalt chloride for 4 hours (A) or 2.4 μg/
ml of insulin for 6 hours (B). Lysates were prepared and Western
blotting was performed using an anti HIF-1a antibody. Lower
panels show blots reprobed for β-tubulin. Asterisks (*) indicate lanes
that were under loaded based on β-tubulin levels. Note the
lowered induction of HIF-1a in the cells lacking both presenilins.
Representative blots are shown from experiments that were
performed multiple times.
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has been implicated as influencing HIF-1a induction
[21,34]. Many of insulin and IGF-1’s cellular effects are
mediated by the PI3K/Akt pathway [40] and induction
of HIF-1a by IGF-1 has been shown to be dependent
on both PI3K/Akt and MAP kinase pathways [21,34].
In at least some cells, insulin’s induction of HIF-1a
also occurs through a PI3K/Akt dependent mechanism
[19]. Psen1 is known to influence signaling through
the PI3K/Akt pathway an effect that is g-secretase
independent [27,29]. Thus failed stimulation through
the PI3K/Akt pathway might explain the lack of HIF-
1a elevation in response to growth factors and if it
affected constitutive HIF-1a synthesis might also
explain the hyporesponsiveness of Psen1-/- fibroblasts
to cobalt chloride if basal levels of HIF-1a synthesis
are decreased.
Therefore we determined whether PI3K/Akt signaling
is impaired in response to IGF-1 or insulin in Psen1-/-
fibroblasts. Interestingly as shown in Figure 6, both IGF-
1 (A) and insulin (B) induced Akt phosphorylation at
Ser473 on a similar time course and to a similar level in
Psen1+/+ and Psen1-/- fibroblasts while total Akt levels
remained unchanged. These studies thus suggest that
Psen1’se f f e c t so nH I F - 1 a induction are not based on
defective signaling through PI3K/Akt pathway.
Lower basal levels of HIF-1a in cells lacking Psen1
If basal levels of HIF-1a were lower in Psen1-/- cells,
this might affect the ability of cells to elevate HIF-1a
protein in response to hypoxia as well as growth
factor stimulation. To determine whether basal levels
of HIF-1a protein were decreased in fibroblasts lacking
Psen1 we examined prolonged exposures of Western
blots from non-stimulated Psen1+/+ and Psen1-/-
fibroblasts. As shown in Figure 7A and 7B, basal
levels of HIF-1a protein were decreased by more than
Figure 5 g-secretase activity is not needed for insulin or cobalt
induction of HIF-1a. Psen1+/+ immortalized fibroblasts (A) were
treated overnight with the g-secretase inhibitor XXI and then
stimulated with insulin for 6 hours. Western blotting for HIF-1a was
performed (upper panel) followed by reprobing of the blot for β-
tubulin (middle panel). The same samples were then reblotted and
probed for N-cadherin (lower panel). A band for the full length N-
cadherin (FL) is indicated. A band that corresponds to the N-
cadherin CTF is visible in the g-secretase inhibitor treated lanes. In
panel B, Psen1+/+ fibroblasts were treated overnight with the g-
secretase inhibitor L-685,458 and then stimulated with cobalt
chloride for 6 hours. The samples were blotted and probed for HIF-
1a (upper panel) and β-actin (middle panel) and then reblotted and
probed for N-cadherin (lower panel). In panel C, the experiment in
(A) was quantitated with the levels of HIF-1a normalized to β-
tubulin. Analysis of the data in panel C (n = 3 per group) revealed
significant increases in HIF-1a following treatment with insulin vs.
untreated control (p = 0.004, unpaired t-test) or XXI treated vs.
insulin + XXI (p = 0.01). There was no difference between insulin
treated vs. insulin plus XXI treated cultures (p = 0.29) although XXI
treatment alone modestly decreased HIF-1a levels vs. untreated
control (p = 0.006). Representative experiments are shown. Asterisks
(*) indicate values that are significantly different from corresponding
samples that were not treated with insulin.
Figure 6 Normal activation by IGF-1 and insulin of PI3K/Akt in
Psen1-/- fibroblasts. Immortalized fibroblast cell lines were treated
with IGF-1 (A) or insulin (B) for the indicated times. Western blotting
was performed for p-Akt (Ser473) followed by reprobing for total
Akt. Panels show representative blots from experiments that were
performed multiple times.
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test). We next determined HIF-1a RNA levels in Psen1
+/+ and Psen1-/- immortalized fibroblasts by qPCR. As
shown Figure 7C, levels of HIF-1a RNA were
decreased by over 50% in Psen1-/- fibroblasts (p =
0.0008). Thus altered HIF-1a RNA levels might contri-
bute to the decreased responsiveness of fibroblasts
lacking Psen1.
Accelerated degradation of HIF-1a in cells lacking Psen1
HIF-1a protein levels are determined by a balance
between synthesis and degradation. Under normoxic
conditions HIF-1a RNA is transcribed and translated at a
constant rate producing a consistent amount of HIF-1a
protein. However in normoxic conditions post-transla-
tional modifications by the prolyl hydroxylases (PHDs)
induce ubiquitination and degradation of HIF-1a
through the proteasome at a rate that exceeds the rate of
synthesis [17]. Indeed under normoxic conditions HIF-
1a has a very short half-life with little HIF-1a protein
accumulating in normal cells [41].
If the low levels of HIF-1a in Psen1-/- fibroblasts were
d u es o l e l yt od e c r e a s e dH I F - 1 a s y n t h e s i sa sm i g h tb e
suggested by the lowered HIF-1a RNA levels then HIF-
1a p r o t e i ns h o u l da c c u m u l a t em o r es l o w l yi nPsen1-/-
fibroblasts if protein degradation was blocked. We tested
this hypothesis by blocking proteasomal degradation of
HIF-1a in Psen1+/+ and Psen1-/- fibroblasts with the
proteasome inhibitor MG132. However, as shown in
Figure 8, although starting at lower basal levels, HIF-1a
protein accumulated at approximately the same rate in
Psen1+/+ and Psen1-/- fibroblasts.
This finding raised the possibility that Psen1 might
influence basal HIF-1a levels not through effects on
synthesis but rather by affecting HIF-1a degradation.
We initially attempted measuring HIF-1a half-life in
Psen1+/+ and Psen1-/- fibroblasts by pulse-chase
experiments using
35S methionine/cysteine followed by
immunoprecipitation (IP) of HIF-1a.H o w e v e rw e
could not detect HIF-1a in either Psen1+/+ or
Psen1-/- fibroblasts (data not shown), an effect that we
suspect is due to the low basal levels of HIF-1a in
most cells. Therefore to determine whether HIF-1a
stability was affected by the absence of Psen1, we trea-
ted Psen1+/+ and Psen1-/- fibroblasts with cyclohexi-
mide to block HIF-1a translation and measured the
rate of HIF-1a degradation. As shown in Figure 9,
t h er a t eo fH I F - 1 a degradation was higher in Psen1-/-
fibroblasts leading to a decrease in HIF-1a half-life
from ≈10 min in Psen1+/+ fibroblasts to less than 5
min in Psen1-/- fibroblasts. Thus degradation of HIF-
1a protein is accelerated in cells that lack Psen1.
Physical interaction between Psen1 and HIF-1a
Psen1 is known to interact with a number of proteins
[42] with this interaction in some cases protecting pro-
teins from degradation through the proteasome [43]
suggesting that one possible explanation for the effects
of Psen1 on HIF-1a stability might be that Psen1 and
HIF-1a physically interact and that this interaction pro-
tects HIF-1a from proteasomal degradation. We there-
fore explored whether Psen1 and HIF-1a might interact
by co-transfecting Psen1 and HIF-1a cDNAs into HEK
293 cells.
As shown in Figure 10, when co-transfected cultures
were immunoprecipitated with Psen1 antibodies that
recognize either the Psen1 NTF or the loop domain,
Western blotting showed co-immunoprecipitation
of HIF-1a (Figure 10A, B). In the reciprocal experi-
ment (Figure 10C), immunoprecipitation of HIF-1a,
followed by Western blotting for Psen1 showed co-
immunoprecipitation of Psen1. In addition, as shown
in Figure 10B endogenous Psen1 co-immunoprecipi-
tated a transfected HIF-1a (last lane to the right in
each panel). Immunoprecipitation of endogenous HIF-
1a with anti-Psen1 antibodies could also be detected
in fibroblasts pretreated with CoCl2 and MG132
Figure 7 Basal levels of HIF-1a are decreased in Psen1-/-
fibroblasts. Shown are prolonged exposures of Western blots from
non-stimulated Psen1+/+ and Psen1-/- fibroblasts. A representative
experiment that was performed multiple times is shown in panel A.
In panel B, the experiment in (A) is quantified (asterisk indicates p =
0.0005, unpaired t-test). In panel C, levels of HIF-1a RNA were
determined in Psen1 +/+ and Psen1-/- fibroblasts by qPCR (n = 3
cultures per group). Samples were run in triplicate and normalized
to the geometric mean of Ppia and Gusb. Asterisk (*) indicates
p = 0.0008.
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and HIF-1a can interact, providing support for the
notion that Psen1 may affect HIF-1a stability by pro-
tecting it from degradation through a direct physical
interaction.
Impaired activation of HIF1-a in fibroblasts harboring the
M146V Psen1 FAD mutation
Psen1 associated FAD mutations are generally thought
of as gain of function mutations that exert their deleter-
ious effect by increasing production of the longer more
amyloidogenic Aβ species [1]. However studies have
suggested that in other contexts Psen1 FAD mutations
may actually be hypofunctional and indeed with regard
to g-secretase function, Psen1 FAD mutations are gener-
ally less efficient than wild type Psen1 in promoting
g-secretase activity [44,45].
Since FAD mutant effects on induction of HIF-1a
could have pathophysiological consequences in AD, we
Figure 8 Synthesis rates of HIF-1a are unchanged in Psen1-/-
fibroblasts. Psen1+/+ (A) and Psen1-/- (B) fibroblasts were treated
with the proteasome inhibitor MG132 for the indicated times (min).
Lysates were prepared and Western blotting was performed using
an anti-HIF-1a antibody. The lower panels show the blots reprobed
for β-tubulin. In panels C and D, the rate of accumulation of HIF-1a
normalized to β-tubulin levels from the experiments in panels A
and B is shown either as the raw data (C) or normalized to basal
levels of HIF-1a in the respective cell types (D). Note that although
basal levels of HIF-1a are lower in Psen1-/- fibroblasts, HIF-1a
accumulated at similar rates in Psen1+/+ and Psen1-/- fibroblasts. A
representative example is shown from experiments that were
performed multiple times.
Figure 9 Accelerated degradation of HIF-1a in Psen1-/-
fibroblasts. Psen1+/+ and Psen1-/- fibroblasts were treated with
cycloheximide. In panel A, a representative experiment is shown
with cells treated for the indicated times. Due to the difference in
basal HIF-1a levels between Psen1 +/+ and Psen1-/- cells, total
protein loaded (15 μg for Psen1+/+ and 30 μg for Psen1 -/-) and
blot exposure times were adjusted so that the signal at time 0’
would be of similar intensity in Psen1+/+ and Psen1-/- cells to
facilitate comparison. In panel B, the % HIF-1a remaining at each
time point normalized to β-tubulin is shown. Data is derived from
the average of three independently performed experiments.
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might affect HIF-1a induction using immortalized fibro-
blasts that express either human wild type Psen1 or the
M146V FAD mutant. These lines were generated from
transgenic mice that express either wild type human
Psen1 from a P1 artificial chromosome (PAC) or FAD
mutant Psen1 generated by retrofitting the PAC with
the M146V FAD mutation [46]. To eliminate the effects
of endogenous mouse Psen1, both PAC transgenes were
bred onto the mouse Psen1-/- background and fibroblast
cell lines were established from transgenic mice. These
transgenic lines express equivalent amounts of wild type
and M146V FAD mutant proteins as judged by Western
blotting [46].
An equally robust activation of HIF-1a was seen in
both wild type and M146V FAD mutant fibroblasts in
response to cobalt chloride (Figure 11A and 11B). By
contrast, when cultures were treated with insulin,
fibroblasts harboring the M146V FAD mutation were
hyporesponsive. While HIF-1a increased more than
10-fold in fibroblasts with the wild type human Psen1,
there was minimal induction of HIF-1a in the M146V
FAD mutant cells (Figure 11C and 11D). Thus hypoxic
induction of HIF-1a is intact in fibroblasts harboring a
Psen1 FAD mutant while metabolic induction is
defective.
To determine whether basal levels of HIF-1a protein
were altered in M146V FAD fibroblasts we examined
prolonged exposures of Western blots from fibroblasts
expressing wild type human Psen1 and the M146V FAD
mutant. As shown in Figure 12, levels of HIF-1a were
not significantly different between fibroblasts expressing
Figure 10 Physical interaction between HIF-1a and Psen1. Expression vectors carrying no insert, Psen1 or HIF-1a were transfected into HEK
293 cells in the indicated combinations. In panel A, immunoprecipitations (IP) were performed with a polyclonal anti-Psen1 antibody which
recognizes the Psen1 NTF or with rabbit IgG as control and Western blotting was performed for HIF-1a. Total extracts without IP (-) (5% of
input) were loaded in the two far right lanes (input). Note the co-immunoprecipitation of HIF-1a in the cultures co-transfected with HIF-1a and
Psen1. A similar experiment was performed in (B), except that immunoprecipitations were performed with the monoclonal antibody NT.1 which
recognizes the Psen1 NTF or with an antibody against the Psen1 loop region. In panel C, immunoprecipitation was done with a monoclonal
HIF-1a antibody followed by Western blotting with an antibody against the Psen1 NTF (NT.1) or CTF (33B10). Panels labeled “none” show blots
of total extracts prior to immunoprecipitation (input). Bands marked with an asterisk (*) are likely IgGs based on the rate of migration. Panel D
shows the co-immunoprecipitation of endogenous HIF-1a by endogenous Psen1. Wild type fibroblasts were treated for 4 hours with 100 μM
CoCl2 and 10 μM MG132 to induce HIF-1a accumulation and co-immunoprecipitations were performed as in (A).
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0.72). These observations thus argue that the effects of
FAD mutant Psen1 on HIF-1a are distinct from the
effects of null mutations in Psen1 and that while
absence of Psen1 reduces basal HIF-1a synthesis, in
FAD mutant cells basal synthesis is intact but metabolic
induction is impaired.
Altered insulin-receptor activation in cells harboring the
Psen1 FAD mutant M146V
We next determined whether lack of HIF-1a induction
in M146V FAD mutant fibroblasts might be related to
impaired signal transduction through the insulin recep-
tor (IR). Binding of insulin to the a subunit of the IR
causes a conformational change in the receptor that
induces autophosphorylation of tyrosine residues in the
β subunit. Figure 13A shows duplicate experiments in
which fibroblasts expressing human wild type and
M146V FAD mutant Psen1 were treated with insulin
and demonstrates that following treatment IR-β is less
phosphorylated in M146V fibroblasts suggesting
decreased receptor activation. Since many of the signal-
ing effects of insulin are mediated through insulin’s acti-
vation of the protein kinase B/Akt pathway [40] we
assessed the phosphorylation of Akt and its target glyco-
gen synthase kinase-3β (GSK-3β). As shown in Figure
13B, Akt was hypophosphorylated following insulin sti-
mulation of M146V FAD mutant containing cells. A
similar result was also seen for GSK-3β (Figure 13C).
Thus responsiveness of the insulin signal transduction
pathway is generally dampened in fibroblasts harboring
the M146V FAD mutation, offering a potential explana-
tion for the impaired activation of HIF-1a.
Psen1-/- primary neuronal cultures activate HIF-1a
normally in response to cobalt chloride but are defective
in HIF-1a induction by insulin and IGF-1
To determine whether HIF-1a induction was impaired
in those cells most relevant to AD, namely neuronal
cells, we prepared primary neuronal cultures from wild
type and Psen1-/- embryos and at 5-6 days in vitro trea-
ted them with cobalt chloride, insulin or IGF-1. As
s h o w ni nF i g u r e1 4 Aa n d1 4 E , unlike fibroblasts, an
equally robust activation of HIF-1a w a ss e e ni nb o t h
wild type and Psen1-/- neuronal cultures in response to
cobalt chloride. By contrast in experiments in which cul-
tures were treated with insulin (Figure 14B, F) or IGF-1
( F i g u r e1 4 C ,D ,G ,H ) ,Psen1-/- neuronal cultures were
hyporesponsive. While HIF-1a increased more than
two-fold in wild type neurons in response to insulin (p
= 0.003) and six-fold in response to IGF-1 (p = 0.01),
there was no significant change in HIF-1a following sti-
mulation of Psen1-/- neurons (p = 0.76 insulin; p = 0.76
IGF-1).
Consistent with the Western blotting data, Vegf RNA
was induced in Psen1-/- n e u r o n sa si nPsen1+/+ at 3
hours after cobalt chloride stimulation (p = 0.007, Figure
15A). Interestingly Vegf RNA tended to increase in
Psen1-/- neurons compared to Psen1+/+ following the
overnight removal of B27 before insulin treatment (p =
0.06, Figure 15B) but did not increase further in
Psen1-/- neurons following insulin stimulation (p =
0.75) in contrast to the approximately two-fold increase
seen in Psen1+/+ neurons (p = 0.007). Thus unlike
fibroblasts, in neuronal cells hypoxic induction of HIF-
1a is intact while as in fibroblasts metabolic induction
is defective.
Figure 11 Altered activation of HIF-1a in fibroblasts harboring the M146V PSEN1 FAD mutation. Fibroblast cell lines harboring human
wild type Psen1 (HuPS1Wt) or the M146V FAD mutant both on the mouse Psen1-/- background were treated with cobalt chloride (A) or insulin
(C) as in Figure 1 for the indicated times (hours). Representative blots are shown from experiments that were performed multiple times. The
experiment in panel A is quantitated in panel B. In panel D, the insulin induction time course in panel C was quantitated. Asterisks (*) indicate
p = 0.04 at 3 hours and p = 0.02 at 6 hours (unpaired t-tests).
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protein were not significantly different between Psen1+/+
and Psen1-/- neurons (Figure 16A, B) and were not
affected by the removal of B27. As in fibroblasts no sig-
nificant difference was seen between Psen1+/+ and
Psen1-/- neurons in the phosphorylation of Akt following
insulin stimulation (Figure 17).
HIF-1a is activated normally during development in
Psen1-/- embryos
Hypoxia is regarded as a strong physiological activator
of HIF-1a during normal development including in the
CNS [47]. To determine whether HIF-1a was activated
in vivo in the absence of Psen1 we performed Western
blotting on wild type and Psen1-/- embryos. Extracts
from whole brain at E14.5 and E18.5 were examined
(Figure 18). HIF-1a expression was easily detectable at
both ages in wild type as well as Psen1-/- embryos and
levels did not significantly vary between genotypes (p =
0.71, E14.5; p = 0.08, E18.5). Thus there appears to be
no defect to HIF-1a activation due to the lack of Psen1
in vivo. However since in vivo activation at this age is
likely driven primarily by hypoxia, these findings can be
seen as consistent with the preservation of hypoxic
induction of HIF-1a in Psen1-/- neuronal cultures
in vitro.
Discussion
Psen1 is a polytopic transmembrane protein that was
first discovered because of its association with FAD
[2,48]. Psen1 influences multiple molecular pathways
being best known for its role as a component of the
g-secretase complex [48]. HIF-1 is a transcription factor
that was first recognized as a DNA-binding protein that
mediates hypoxia-inducible expression of the erythro-
poietin (EPO) 3′ enhancer. It is now known that HIF-1
is a key transcriptional regulator of a wide variety of cel-
lular genes that are induced by and regulate cellular
responses to hypoxia [16,17,49,50].
Here we show that Psen1 regulates induction of HIF-
1a. Specifically we demonstrate that there is impaired
induction of HIF-1a in fibroblasts lacking Psen1 follow-
ing stimulation with the hypoxia mimetic cobalt chloride
as well as treatment with insulin and calcium chelation.
Associated with impaired induction there was reduced
and delayed activation of the HIF-1a target genes Vegf
and Glut-1. We further show that decreased basal levels
of HIF-1a best account for this impairment in fibro-
blasts lacking Psen1.
Depressed levels of basal HIF-1a in Psen1-/- fibro-
blasts may in part be the result of lowered levels of
HIF-1a RNA. However the ≈ 50% reduction in HIF-1a
RNA levels did not appear sufficient to explain the
more than 5-fold reduction in basal levels of HIF-1a
protein in Psen1-/- fibroblasts. Rather these results sug-
gested that in addition either constitutive synthesis of
HIF-1a was decreased at a post-transcriptional level or
that constitutive degradation was increased. In further
studies we found that increased degradation best
accounts for these effects showing that when proteaso-
mal degradation of HIF-1a was blocked, HIF-1a levels
accumulated as rapidly in Psen1-/- fibroblasts as in
Figure 12 Basal levels of HIF-1a are unchanged in M146V FAD
mutant fibroblasts. Shown are prolonged exposures of Western
blots from the fibroblast lines studied in Figure 11. In panel A,
representative blots are shown of samples from individual cultures
harboring the human wild type Psen1 (HuPS1Wt) or the M146V FAD
mutant. The lower panel shows the blot reprobed for β-tubulin. In
panel B, levels of HIF-1a were determined by quantitative Western
blotting (n = 5 cultures per genotype) with the levels of HIF-1a
normalized to the levels of β-tubulin. Studies were performed both
in the presence of serum (FBS) and after overnight serum starvation
(-FBS). There were no statistically significant differences between the
HuPS1Wt and M146V FAD mutant cell lines.
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blocked with cycloheximide levels of HIF-1a decreased
more rapidly in Psen1-/- fibroblasts than Psen1+/+ with
an approximate 50% reduction in HIF-1a half-life.
Mechanistically we show that Psen1’s g-secretase activ-
ity is not needed for HIF-1a induction by insulin nor
cobalt chloride and that in the case of insulin induction
of HIF-1a, impaired signaling through the PI3K/Akt
pathway cannot account for the effect. Rather we show
that Psen1 and HIF-1a physically interact suggesting
that Psen1 may stabilize HIF-1a and protect it from
degradation.
Both mouse and human Psen1 are initially produced
as an ≈ 45-48 kDa holoprotein. However, in most cells
and tissues nearly all of the holoprotein is cleaved into
an ≈ 30 kDa NTF and an ≈18 kDa CTF, that are
produced by endoproteolytic cleavage within a large
cytoplasmic loop region [48]. NTFs and CTFs associate
with each other as heterodimeric components of a larger
multimeric protein complex. After incorporation into
these high molecular weight complexes, NTFs and CTFs
remain associated and attain relatively long half-lives.
Our co-IP studies suggest that HIF-1a associates with
both the Psen1 NTF and CTF and likely forms a part of
these complexes. Psen1 holoprotein that remains mono-
meric is rapidly degraded by a proteasome-dependent
mechanism [51,52] and complex incorporation is likely
necessary for the biological activity of presenilins [48].
Psen1 and 2 proteolysis is also regulated by the protea-
some interacting proteins ubiquilin-1 and -2 [53-55] and
Psen1 influences proteasomal degradation of another
component of the g-secretase complex Pen-2 [43].
Figure 13 Decreased insulin-induced activation of the insulin receptor, Akt and GSK-3β in fibroblasts harboring the M146V Psen1 FAD
mutation. In panel A, human wild type Psen1 (HuPS1Wt) or M146V FAD mutant cell lines were serum starved overnight and then stimulated
with insulin for the indicated times. Western blotting for the phosphorylated IR receptor β (Tyr 1150/1151) or total IR is shown in experiments
run in duplicate. The pro-insulin receptor and processed IR are indicated. In panel B, duplicate experiments are shown following Western
blotting for p-Akt (Ser473) and total Akt. p-Akt panels are shown at two different exposures. Lower panel shows the blot reprobed for β-tubulin
as a loading control. In panel C, the extracts were blotted and probed for p-GSK-3β (Ser9) and total GSK-3β. In panels D, E and F the relative
increase in p-IR/total IR (D), p-Akt/total Akt (E) and p-GSK-3β/total GSK-3β (F) are shown for the experiments in A-C.
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similar to the effects of Psen1 on HIF-1a with in both
cases the absence of Psen1 leading to accelerated pro-
tein degradation through the proteasome. Interestingly,
overexpression of Psen1 has also been reported to
increase levels of HIF-1β in pancreatic islet cells [56]
pointing to a possibly larger role of Psen1 in HIF-1 sig-
naling although the mechanistic basis for Psen1’s effect
on HIF-1β is unknown.
In contrast to the more global effects that the absence
of Psen1 has in fibroblasts, hypoxic signaling proceeded
normally in Psen1-/- neurons and in fibroblasts harbor-
ing the M146V FAD mutation while in these same cells
metabolic signaling through insulin and IGF-1 was
impaired. HIF-1a levels were also normal in Psen1-/-
embryos arguing that activation in neuronal cells during
development which is probably mostly driven by
hypoxia [47] can proceed normally without Psen1.
Figure 14 Altered induction of HIF-1a in Psen1-/- primary neuronal cultures. Primary neuronal cultures were prepared from E15.5-16
embryonic brains and maintained in Neurobasal medium/B27 supplement. Experiments were performed after 5-6 days in vitro. In panel A,
cultures were treated with 100 μm cobalt chloride for the indicated times (hrs). In panels B and C, cells were cultured without B27 overnight
and then treated with insulin (B) or IGF-1 (C) for six hours. In panel D, cells were cultured without B27 overnight and then treated with IGF-1 for
the indicated times. Western blotting for HIF-1a was performed as in Figure 1 and the lower panels show the same blots reprobed for β-tubulin
or actin. In panels E and H, the time course of the studies in (A) and (D) are quantitated. The insulin and IGF-1 studies in panels B and C are
quantitated in (F) and (G). All panels show representative blots from experiments that were performed multiple times. Asterisks indicate p < 0.05
vs. untreated control (unpaired t-tests).
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effects on protein degradation by the proteasome, meta-
bolic/growth factor stimulation principally increases
HIF-1a protein synthesis by stimulating transcription/
translation while degradation proceeds at a constant
rate [33]. Of these two pathways, hypoxic induction of
HIF-1a results in more dramatic elevations of HIF-1a
than metabolic/growth factor stimulation likely because
degradation is the key rate limiting step in setting basal
HIF-1a levels while factors such as insulin and IGF-1
induce HIF-1a by stimulating synthesis on a back-
ground of continued degradation.
Interestingly, unlike in Psen1-/- fibroblasts, basal
levels of HIF-1a were not reduced in fibroblasts har-
boring the M146V FAD mutation or in Psen1-/- pri-
mary neurons. While the basis for these differences in
HIF-1a basal levels remains to be explained, they pro-
vide a potential explanation for why HIF-1a respon-
siveness differs between cell types in that hypoxic
induction of HIF-1a depends on a basal level of HIF-
1a being present. Metabolic/growth factor induction
being weaker requires a higher basal level of HIF-1a to
be present in order to produce detectible induction.
Since Psen1-/- fibroblasts have dramatically reduced
levels of basal HIF-1a neither hypoxic nor metabolic/
growth factor induction is possible. By contrast in
FAD mutant fibroblasts or Psen1-/- primary neurons, a
basal level of HIF-1a is present that is sufficient to
support hypoxic induction while metabolic/growth fac-
tor induction is impaired.
Of the metabolic pathways implicated in HIF-1a regu-
lation the PI3K/Akt and MAP kinase are the best-docu-
mented [33] and many of insulin’sa sw e l la sI G F - 1 ’s
cellular effects are mediated by the PI3K/Akt pathway
[40]. In at least some cells, insulin’s induction of HIF-1a
has been shown to occur through a PI3K/Akt dependent
mechanism [19] and induction of HIF-1a by IGF-1 has
also been shown to be dependent on PI3K/Akt activa-
tion [21,34]. Psen1 is known to influence signaling
through the PI3K/Akt pathway, an effect that is g-secre-
tase independent [27,29].
Interestingly we did not find effects on PI3K/Akt induc-
tion in Psen1-/- fibroblasts or neurons although we found
that in fibroblasts harboring the Psen1 M146V FAD
mutant insulin receptor activation as well as activation of
PI3K/Akt and Akt’s downstream target GSK-3β were
impaired. Thus while a direct effect of Psen1 on insulin/
IGF-1 signaling might explain the failed activation of HIF-
1a in FAD mutant fibroblasts, it cannot account for the
failed activation in Psen1-/- neurons. Future studies will be
Figure 15 Activation of HIF-1a downstream target genes in
Psen1-/- neurons treated with cobalt chloride or insulin. Levels
of Vegf RNA were determined by qPCR following three hours of
treatment of wild type or Psen1-/- primary neuronal cultures with
cobalt chloride (A, n = 3 cultures per group) or seven hours with
insulin (B, n = 2 cultures per group). Samples were run in triplicate
and normalized to Ppia. Asterisks indicate p < 0.01 vs. untreated
control (unpaired t-tests). Figure 16 Basal levels of HIF-1a RNA and protein are not
significantly changed in Psen1-/- neurons. Basal HIF-1a RNA and
protein were measured in neurons in the presence and absence of
B27 supplement. In panel A, HIF-1a RNA was measured in neuronal
cultures (n = 3/genotype) by qPCR. Samples were run in triplicate
and normalized to the geometric means of Ppia and Gusb. In panel
B, basal levels of HIF-1a protein were measured in neurons by
Western blotting (n = 6 for cultures with B27 and n = 10 for B27
starved cultures). No statistically significant differences were found
among the samples (unpaired t-tests). In panel C, representative
Western blots are shown of cells cultured with B27 or without
(-B27).
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as the differences between the effects of the absence of
Psen1 and the presence of Psen1 FAD mutants.
The implications of these observations for the patho-
physiological effects of Psen1 FAD mutations remains
speculative. Insulin receptors are expressed widely in
brain including areas involved in AD such as the hippo-
campus [57]. The widespread expression of insulin
receptors in brain suggests that insulin signaling plays a
significant functional role in brain and indeed signaling
through the insulin receptori sk n o w nt oi n f l u e n c ea
wide variety of cellular functions related to cellular
homeostasis and growth factor signaling including
affecting synaptic transmission and neurotransmitter
levels as well as exerting effects on learning and memory
[58,59]. IGF-1 signaling is also of interest since it has
many links to brain function as well as potential patho-
physiological connections to neurodegenerative diseases
including AD [60-63]. There has also been much inter-
est in the potential role of insulin resistance in AD with
most epidemiologic studies suggesting diabetes to be a
risk factor for AD [64]. Diabetes and anti-diabetic medi-
cation have also been shown to influence AD related
neuropathology [65,66].
Both insulin and IGF-1 signaling have connections to
Aβ production [67-74] and tau phosphorylation [75-80]
as well as have roles in modulating neural inflammatory
reactions and neuronal apoptosis [81,82]. Thus an effect
of Psen1 FAD mutations on insulin and IGF-1 related
signaling could impact AD-related pathology including
but not limited to effects on HIF-1a induction.
Conclusions
Yet whatever the pathophysiological implications for
Psen1 associated FAD mutations, our observations
show 7that Psen1 is needed for the normal induction of
Figure 17 Normal activation by insulin of PI3K/Akt in Psen1-/-
neurons. Primary neuronal cultures were treated with insulin for
the indicated times. In panel A, Western blotting was performed for
p-Akt (Ser473) followed by reprobing for total Akt. Shown are
representative blots from experiments that were performed multiple
times. In panel B, the time course of induction of p-Akt in primary
neuronal cultures (n = 2 per genotype per time point) is shown as
a ratio of p-Akt/total Akt. There were no significant differences at
any time point (unpaired t-tests).
Figure 18 No change in HIF-1a levels in Psen1-/- embryonic
brain. HIF-1a levels were determined by Western blotting of
extracts from E14.5 (A) or E18.5 (B) brain from wild type (wt) or
homozygous (-/-) Psen1 mutant mice. Representative experiments
are shown. Lower panels show the same blots reprobed for β-
tubulin. HIF-1a levels were quantitated as a ratio to β-tubulin at
E14.5 (C) and E18.5 (D) (n = 4 wild type and 2 Psen1-/- at each age).
There were no differences between wild type (wt) and Psen1-/- at
either age (unpaired t-tests).
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impairs aspects of HIF-1a induction. Future studies in
Psen1 FAD mutant mice will be needed to further clar-
ify the role that HIF-1a signaling may play in the patho-
physiological changes seen in these mice [83].
Materials and methods
Genetically modified mice
The Psen1-/- mice utilized were those generated by
Shen et al. [84]. These animals were provided on a
mixed genetic background and have been maintained by
breeding to C57BL/6 wild type mice. Genotypes were
determined by PCR utilizing primers from the Psen1
intron 1 (5’ACCTCAGCTGTTTGTCCCGG3’), the neo
gene (5’GCACGAGACTAGTGAGACGTG3’)a n dPsen1
exon 3 (5’TCTGGAAGTAGGACAAAGGTG3’)a s
described in Shen et al. [84]. Heterozygous mice were
mated to produce Psen1-/- embryos with the day a vagi-
nal plug was detected designated as E0.5. Pregnant
female mice were euthanized with carbon dioxide and
Psen1-/- embryos were presumptively identified based
on their gross dysmorphic appearance. A portion of the
body was saved and used to isolate DNA and confirm
genotypes. Due to the mixed genetic background, Psen1
+/+ and Psen1+/- littermates were used as controls.
Since Psen1+/- mice have never been observed to exhi-
bit any developmental abnormalities, they were treated
as wild type controls.
Transgenic mice expressing wild type human Psen1
from a P1 bacteriophage artificial chromosome (PAC)
were produced using the clone RP1-54D12 (204 kb;
accession number AC 006342) containing the entire
human Psen1 transcription unit (> 75 kb). Founders
were generated by injecting C57BL/6 × C3 H F1 oocytes.
In order to generate PAC transgenic mice expressing
the M146V FAD mutation, the 54D12 clone was retro-
fitted using the Rec A-mediated homologous recombina-
tion system described by Ali Imam et al. [85] and
transgenic founders were generated as described above.
Further details concerning production and characteriza-
tion of the Psen1 wild type and FAD mutant PAC trans-
genic mice can be found elsewhere [46]. All protocols
were approved by the Institutional Animal Care and Use
Committees of the James J. Peters Department of Veter-
ans Affairs Medical Center (Bronx, NY, USA) and the
Mount Sinai School of Medicine (New York, NY, USA)
and were conducted in conformance with Public Health
S e r v i c e( P H S )p o l i c yo nt h eh u m a n ec a r ea n du s eo f
laboratory animals and the NIH Guide for the Care and
Use of Laboratory Animals.
Cell culture
Generation of immortalized Psen1+/+ and Psen1-/-
mouse embryonic fibroblasts has been described
previously [27]. Immortalized fibroblast lines were also
developed from the Psen1 wild type and M146V PAC
transgenic mice described above. In order to eliminate
effects of the endogenous mouse Psen1, both PAC trans-
genic lines were bred onto the mouse Psen1-/- back-
ground and fibroblast cell lines were established from
E16.5 embryos. After removing the head and liver,
embryos were finely minced and treated with 0.25%
trypsin (Invitrogen, Carlsbad, CA, USA), 0.1% EDTA.
Trypsinized tissues were plated in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 20% heat-
inactivated fetal calf serum (Mediatech, Manassas, VA,
USA), penicillin, streptomycin, fungizone, and glutamine
(Invitrogen) at 37°C in 5% CO2. Explanted cells were
continuously passed in the same medium until lines
were established. Fibroblast cell lines lacking both prese-
nilins (Psen-/-)w e r eag i f tf r o mD r .N i k o l a o sR o b a k i s
(Mount Sinai School of Medicine, New York, NY, USA).
Immortalized fibroblasts were maintained in DMEM
medium supplemented with 20% FCS at 37°C and 5%
CO2. To study HIF-1a induction under hypoxic condi-
tions confluent cells were treated with the hypoxia
mimetic CoCl2 (100 μM, Sigma Aldrich, St. Louis, MO,
USA) for 4 hrs. For insulin or IGF-1 treatment, cells
were serum starved overnight and treated with 2.4 μg/
ml of insulin (porcine pancreas, Sigma Aldrich) or 100
ng/ml IGF-1 (Sigma Aldrich) for 4-6 hours. Cells were
washed with phosphate buffered saline (PBS) and lysed
in 10 mM Na phosphate buffer, pH 7.4, 150 mM NaCl,
2 mM EDTA, 1%Triton X-100, 0.25% Na deoxycholate,
and 0.5% SDS, supplemented with HALT protease inhi-
bitor cocktail (Pierce, Rockford, IL, USA) and phospha-
tase inhibitor cocktails I and II (Sigma Aldrich). The
lysates were briefly sonicated and centrifuged at 14,000
rpm for 15 min. The cleared supernatant was then col-
lected. Protein concentrations were determined with the
BCA reagent (Pierce).
In some experiments Psen1 +/+ and Psen1-/- fibro-
blasts at ≈70% confluence were treated with 5 μM1 , 2 -
bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid
tetrakis (acetoxymethylester) (BAPTA-AM, Sigma
Aldrich), 10 μm MG132 (Calbiochem, San Diego, CA,
USA), or 100 μg/ml cycloheximide (Sigma-Aldrich). For
g-secretase inhibition experiments, Psen1 +/+ cultures
were treated overnight with 1 μM inhibitor XXI (also
known as compound E, Calbiochem) or 1 μM L-685,458
(Calbiochem).
Primary neuronal cultures were prepared from the cer-
ebral cortex isolated from E15.5-16 embryos as pre-
viously described [86,87] and maintained in Neurobasal
medium/B27 supplement (Invitrogen) for 5-7 days in
vitro (DIV). For treatment with insulin or IGF-1, neurons
were maintained overnight in neurobasal medium devoid
of B27 supplement and then treated as described above.
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Brains were homogenized in 10 volumes of RIPA buffer
(50 mM Tris HCl, pH 7.6, 0.15 M NaCl, 1 mM EDTA,
1% Triton X100, 1% sodium deoxycholate, 0.1% SDS)
containing HALT protease and phosphatase inhibitor
cocktails (Pierce Biotechnologies). The samples were
centrifuged at 15,000 rpm for 20 minutes and the super-
natant collected. Protein concentrations were deter-
mined using the BCA reagent assay (Pierce).
Western Blotting
Protein samples were separated by SDS-PAGE and
blotted onto polyvinylidene difluoride (PVDF) mem-
branes (Millipore Corporation, Billerica, MA, USA).
Blots were blocked with 50 mM Tris HCl, pH 7.6, 0.15
M NaCl, 0.1% Tween-20 (TBST), 5% non fat dry milk
and probed overnight with the relevant primary anti-
body diluted in blocking solution or in 5% BSA/TBST
in the case of phospho-specific antibodies. Blots were
then incubated for 1.5 hours with the appropriate horse-
radish peroxidase (HRP) conjugated secondary antibody
(GE Healthcare Bio-Sciences Corporation, Piscataway,
NJ, USA) diluted in blocking solution (1:5000-1:10,000)
and bands visualized by ECL+ (GE Biosciences) after
exposure to CL-Xposure film (Pierce) and/or imaged on
a Kodak Image Station 4000R (Carestream Molecular
Imaging, New Haven, CT, USA). Quantification was
performed using Image Quant TL software (GE Bios-
ciences). For reprobing, the membranes were treated
with Re-Blot Plus strong stripping solution (Millipore)
according to the manufacturer’s instructions.
The primary antibodies utilized were rabbit polyclonal
(1:1500 dilution; Novus Biologicals, Littleton, CO, USA)
or monoclonal (Mab5382, 1:1000; Millipore) antibodies
to HIF-1a, a monoclonal antibody to the cytoplasmic
domain of N-cadherin (1:1000; BD Biosciences, San
Jose, CA, USA), rabbit monoclonal antibodies to phos-
pho-Akt (Ser473), total Akt, phospho-GSK-3β (Ser9),
total GSK-3β, and the phospho-insulin receptor (all at
1:1500 dilutions; Cell Signaling, Beverly, MA, USA), as
well as a mouse monoclonal antibody to the insulin
receptor β (MAB 1139, 1:500; Millipore). Mouse mono-
clonal anti-actin antibody AC15 (1:500; Sigma Aldrich)
or rabbit polyclonal anti β-tubulin (1:1500; Abcam,
Cambridge, UK) antibodies were used as loading
controls.
Lentivirus infection
A lentiviral construct (2 μg) containing human Psen1
cloned in vector pReceiver-LV31 (Z 0049, Genecopeia,
Rockville, MD, USA) was transfected with 10 μgo ft h e
packaging plasmids pLV-PK-FIV and pLV-PK-VSG
(Genecopeia) into 293Ta cells using the Lipofectamine
reagent (Invitrogen). Forty-eight hours post-tranfection
the culture supernatant containing the recombinant len-
tiviruses was centrifuged for 10 minutes at 1500 rpm to
clear debris and filtered through a 0.45 μm PVDF filter.
To infect fibroblasts 1 ml of the lentiviral supernatant
containing 8 μg/ml of polybrene was added (multiplicity
of infection = 10). After overnight incubation, the viral
supernatant was replaced with DMEM containing 20%
fetal calf serum and cultured for 48 h. The cells were
then treated with cobalt chloride and analyzed for HIF-
1a as described above.
Co-immunoprecipitations
An expression ready plasmid for mouse HIF-1a (clone
ID 4019056) was obtained from Open Biosystems
(Huntsville, AL, USA) and for human Psen1 (clone
sc125532) from Origene (Rockville, MD, USA). Psen1
and HIF-1a expression plasmids (3 μg each) or empty
vector were transfected singly or together into HEK293
cells using the Fugene 6 reagent as recommended by
the manufacturer (Roche, Indianapolis, IN, USA). After
48 hours cells were treated for 1 hour with 100 μM
MG132 and harvested. The cells were lysed in an IP
buffer consisting of 50 mM Tris HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 0.5% NP-40 supplemented with a
protease inhibitor cocktail (Halt, Pierce) and phospha-
tase inhibitor cocktails I and II (Sigma Aldrich). Lysates
(500-750 μg protein) were pre-cleared with protein A/G
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2
hours and then incubated overnight at 4°C with one of
the following antibodies: rabbit anti-Psen1 NTF (1 μg;
Santa Cruz), mouse monoclonal antibody NT.1 which
recognizes the NTF of human Psen1 (3 μg, gift of Dr.
Paul Mathews, Nathan Kline Institute, Orangeburg, NY,
USA), a mouse monoclonal anti-Psen1 loop antibody (2
μg, MAB5232 Millipore), a mouse monoclonal anti-HIF-
1a antibody (3 μg, clone ESEE 122, Novus) or rabbit
IgG (Santa Cruz). 20 μl of protein A/G was then added
for 2 hours at 4°C and the samples were washed 4 times
(20 min each) with IP buffer. SDS-PAGE buffer was
added and samples were boiled or for Psen1 blots
heated at 50°C for 10 minutes and analyzed by Western
blot using the antibodies described as well as the mouse
monoclonal antibody 33B10 (1:3,000, gift of Dr. Niko-
laos Robakis, Mount Sinai School of Medicine, New
York, NY, USA) which recognizes both the human and
mouse Psen1 CTF. Clean-Blot IP HRP detection reagent
(Pierce) was used to minimize reactivity with denatured
IgG in co-immunoprecipitations when the blots were
probed with rabbit polyclonal antibodies. For co-immu-
noprecipitation of endogenous HIF-1a in Psen1+/+
fibroblasts, cells were treated with 100 μMC o C l 2 and
10 μM MG132 for 4 hours and then immunoprecipita-
tions were performed with anti-Psen1 antibodies as
described above.
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Page 17 of 20Quantitation of mRNA expression by real time
quantitative PCR
Total RNA was isolated from cultured cells using the
Ribopure kit (Ambion, Austin, TX, USA). Residual
genomic DNA was removed using the DNA-free kit
(Ambion) and cDNA was synthesized from 0.8 μgo f
total RNA using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA,
USA). Real-time quantitative polymerase chain reaction
(qPCR) was performed using an ABI Prism 7500 or
7700 Sequence Detector and TaqMan FAM/MGB gene-
specific fluorogenic assays mostly as previously
described [88]. Pre-designed TaqMan Gene Expression
assays (probe and primer mix) for all target and control
genes were purchased from Applied Biosystems
(Mm00437304_m1 VegfA, Mm00441480 Glut-1,
Mm00468875_m1 HIF-1a, Mm00446953_m1 Gusb and
Mm02342429_m1 Ppia). Each 20 μl reaction contained
5 μl of the relevant cDNA (diluted 25 times in H2O), 1
μl of a specific TaqMan assay, and 10 μlo ft h e2 × P C R
Universal Master Mix (Applied Biosystems). The ther-
mal cycling program consisted of 2 min at 50°C, 10 min
at 95°C, followed by 40 cycles of 15 sec at 95°C and 1
min at 60°C. Only one cDNA was amplified in each
qPCR (monoplex). The reactions were run in triplicate
for each sample. Relative expression values of target
genes were calculated using the 2
DDCt method [89], with
the amount of target normalized to the geometric mean
of the expression values for the endogenous control
genes peptidylprolyl isomerase A (Ppia) and Glucuroni-
dase beta (Gusb) relative to a calibrator (generated by
pooling all the samples).
Statistical procedures
All data are presented as mean ± the standard error of
the mean (S.E.M.). Statistical comparisons were made
using unpaired t-tests (Student’s t if the variances did
not differ significantly, p > 0.05, by Levene’s test; other-
wise the Welch correction for unequal variances) or
one-way analysis of variance (ANOVA) with Dunnett’s
post-test. Statistical tests were performed using the pro-
gram GraphPad Prism 5.0 (GraphPad Software, San
D i e g o ,C A ,U S A )o rS P S S1 6 . 0( S P S S ,C h i c a g o ,I L ,
USA).
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